Document:

Exhibit 10(b)

  POWER OF ATTORNEY

  

  

  We, the undersigned directors and/or officers of Lincoln Life & Annuity Company of New York, hereby constitute and appoint Delson R. Campbell, Scott C. Durocher, Kimberly A. Genovese, Daniel P. Herr, Donald E. Keller, Michelle Grindle, Jeffrey L. Smith, Jassmin McIver-Jones, Carolyn Augur and John D. Weber, individually, our true and lawful
    attorneys-in-fact, with full power to each of them to sign for us, in our names and in the capacities indicated below, any Registration Statements and any and all amendments to Registration Statements; including exhibits, or other documents filed on
    Forms N-6 or N-4 or any successors or amendments to these Forms, filed with the Securities and Exchange Commission, under the Securities Act of 1933 and/or Securities Act of 1940, on behalf of the Company in its own name or in the name of one of its
    Separate Accounts, hereby ratifying and confirming our signatures as they may be signed by any of our attorneys-in-fact to any amendment to said Registration Statements as
    follows:

  

  

  Variable Life Insurance Separate Accounts:

  

  

  	
          Lincoln Life & Annuity Flexible Premium Variable Life Account M (811-08559)

        	
          VUL-I / VULcv

          VULcv-II / VUL Flex ES

          VULcv-III ES

          VULdb / VULdb ES

          VULdb-II ES

          VULone ES / VULone 2005 ES

          Momentum VULone / Momentum VULone 2005

          VULcv-IV ES

          VULdb-IV ES

          AssetEdge VUL

          AssetEdge VUL/AssetEdge Exec VUL 2015

          VULone 2007

          VULone 2010

        
	
          LLANY Separate Account R for Flexible Premium Variable Life (811-08651)

        	
          SVUL / SVUL ES

          SVUL-II ES

          SVUL-III ES

          SVUL-IV ES/PreservationEdge SVUL

          SVULone ES

          Momentum SVULone

          SVULone 2007

        
	
          LLANY Separate Account S for Flexible Premium Variable Life (811-09257)

        	
          CVUL Series III ES

          LCV4 ES

          LCV5 ES / LCC VUL

        
	
          Lincoln Life & Annuity Flexible Premium Variable Life Account Y (811-21029)

        	
          American Legacy VULcv-III

          American Legacy VULdb-II

          American Legacy SVUL-III

          American Legacy VULcv-IV

          American Legacy VULdb-IV

          American Legacy SVUL-IV/PreservationEdge SVUL

          American Legacy AssetEdge

        

  

  

  

  

  

  

  

  

  Variable Annuity Insurance Separate Accounts:

  	
          Lincoln Life & Annuity Variable Annuity  Account H (811-08441)

        	
          American Legacy III

          American Legacy III B Class

          American Legacy III C Share

          American Legacy III Plus

          American Legacy III View

          American Legacy Design

          American Legacy Signature

          American Legacy Fusion

          American Legacy Series

          American Legacy Advisory

          American Legacy Target Date Income B Share

          American Legacy Target Date Income Advisory

          Shareholder’s Advantage

          Shareholder’s Advantage A Class

        
	
          Lincoln Life & Annuity Variable Annuity Account L (811-07785)

        	
          Group Variable Annuity

        
	
          Lincoln New York Account N for Variable Annuities (811-09763)

        	
          ChoicePlus Assurance (A Share)

          ChoicePlus Assurance (A Class)

          ChoicePlus Assurance (B Share)

          ChoicePlus Assurance (B Class)

          ChoicePlus Assurance (C Share)

          ChoicePlus Assurance (L Share)

          ChoicePlus Assurance (Bonus)

          ChoicePlus

          ChoicePlus II

          ChoicePlus Access

          ChoicePlus II Access

          ChoicePlus II Advance

          ChoicePlus II Bonus

          ChoicePlus Design

          ChoicePlus Signature

          ChoicePlus Fusion

          ChoicePlus Series

          ChoicePlus Prime

          ChoicePlus Advisory

          ChoicePlus Select B-Share

          Lincoln InvestmentSolutions

          Lincoln Investor Advantage

          Lincoln Investor Advantage 2018

          Lincoln Investor Advantage Fee-Based

          Lincoln Investor Advantage Advisory

          Lincoln Investor Advantage Advisory Choice

          Core Income

        

  

  

  Except as otherwise specifically provided herein, the power-of-attorney granted herein shall not in any manner revoke in whole or in part any power-of-attorney that
    each person whose signature appears below has previously executed.  This power-of-attorney shall not be revoked by any subsequent power-of-attorney each person whose signature appears below may execute, unless such subsequent power specifically refers
    to this power-of-attorney or specifically states that the instrument is intended to revoke all prior general powers-of-attorney or all prior powers-of-attorney.

  

  

  This Power-of-Attorney may be executed in separate counterparts each of which when executed and delivered shall be an original; but all such counterparts shall
    together constitute one and the same instrument.  Each counterpart may consist of a number of copies, each signed by less than all, but together signed by all, of the undersigned.

  

  

  

  

  Signature                                                                                    Title

  

  

  /s/Dennis R. Glass

  	______________________________	
          President and Director

        

  Dennis R. Glass

  

  

  /s/Ellen G. Cooper

  ______________________________                                                                                                  Executive Vice President, Chief Investment Officer Ellen G. Cooper  and Director

  

  

  /s/Randal J. Freitag

  ______________________________                                                                                                  Executive Vice President; Chief Financial Officer Randal J. Freitag  and Director

  

  

  /s/Christine A. Janofsky

  ______________________________                                                                                                  Senior Vice President; Chief Accounting Officer Christine A. Janofsky  and Controller

  

  

  /s/Lisa M. Buckingham

  ______________________________                                                                                                  Director

  Lisa M. Buckingham

  

  

  /s/George W. Henderson, III

  ______________________________                                                                                                  Director

  George W. Henderson, III

  

  

  /s/Mark E. Konen

  ______________________________                                                                                                  Director

  Mark E. Konen

  

  

  /s/M. Leanne Lachman

  ______________________________                                                                                                  Director

  M. Leanne Lachman

  

  

  /s/Louis G. Marcoccia

  ______________________________                                                                                                  Director

  Louis G. Marcoccia

  

  

  /s/Patrick S. Pittard

  _______________________________                                                                                                  Director

  Patrick S. Pittard

  

  

  

  

  

  

  We, Delson R. Campbell, Scott C. Durocher, Kimberly A. Genovese, Daniel P. Herr, Donald E. Keller, Michelle Grindle, Jeffrey L. Smith, Jassmin McIver-Jones,
    Carolyn Augur and John D. Weber, have read the foregoing Power of Attorney.  We are the person(s) identified therein as agent(s) for the principal named therein.  We acknowledge our legal responsibilities.

  

  

  	
          /s/Delson R. Campbell                                                      

          Delson R. Campbell

           

        	
          /s/Scott C. Durocher  

          Scott C. Durocher

        
	
          /s/Kimberly A. Genovese                                                      

          Kimberly A. Genovese

           

        	
          /s/Daniel P. Herr                                                      

          Daniel P. Herr

        
	
          /s/Donald E. Keller                                                      

          Donald E. Keller

           

        	
          /s/Michelle Grindle                                                      

          Michelle Grindle

        
	
          /s/Jeffrey L. Smith                                                      

          Jeffrey L. Smith

           

        	
          /s/John D. Weber                                                      

          John D. Weber

        
	
          /s/Jassmin McIver-Jones                                                      

          Jassmin McIver-Jones

        	
          /s/Carolyn Augur                                                      

          Carolyn Augur

        

  

  

  

  

  

  

  

  

  Version:  May 2020ex_199569.htm

Exhibit 10.6

 

**Information contained in portions of this Exhibit has been redacted because the Company has determined that such information (i) is not material and (ii) would likely cause competitive harm to the Company if it were to be publicly disclosed.  Information redacted from this Exhibit has been marked by the following [**].

 

 

August 11, 2020

 

 

 

TO WHOM IT MAY CONCERN

 

SUBJECT; LETTER OF AUTHORIZATION

 

 

The above subject refers.

 

We, BIOHIT HEALTHCARE (HEFEI) CO., LTD. locating at Building D9 floor 1-4, Innovation Park, No.800 West Wangjiang Road, High-Tech Zones, hereby authorize ThermoGenesis Holdings, Inc. a duly incorporated company with primary office at 2711 Citrus Road, Rancho Cordova, CA 95742, U.S.A., as our authorized distributor to market, sell and distribute our test kits for SAR-CoV-2 Coronavirus (COVID-19) in United States. Its order will be taken as priority.

 

 

We are looking forwards to your kind cooperation and patronage.

 

 

Best regards

 

 

	Expiry Date: August 11, 2021
	 
	
			/s/ Liu Feng

			
	 

 

 

 

 

/s/ XX

 

 

 

 

 

Note:

 

To ensure the legality and validity of the authorization, the distributor and BIOHIT need to meet the requirements of FDA as following:

 

 

Biohit Healthcare {Hefei) Co. Ltd. (Biohit) and Authorized Distributor(s)

 

A. Biohit's product must comply with the following labeling requirements under FDA regulations: the intended use statement (21 CFR 809.10(a)(2), (b)(2)); adequate directions for use (21 U.S.C. 352(f)), (21 CFR 809.lO(b)(S), (7), and (8)); appropriate limitations on the use of the device including information required under 21 CFR 809.10(a)(4); and any available information regarding performance of the device, including requirements under 21 CFR 809. l0(b)(12).

 

 

B. Biohit and authorized distributor(s) will make Biohit product available with the authorized labeling to authorized laboratories. Biohit may request changes to the authorized labeling. Such requests will be made in consultation with, and require concurrence of, 5 "Authorized Distributor(s)" are Identified by Biohit Healthcare (Hefei) Co. ltd., in the EUA submission as an entity allowed to distribute Biohit device. Page 5 - Brian Yang, Biohit Healthcare (Hefei) Co. Ltd.

DMD/O HT7-0I R/OPEQ/ CDRH.

 

 

C. Biohit and authorized distributor(s) will make available on Biohit's website(s) the Fact Sheet for Healthcare Providers and the Fact Sheet for Recipients.

 

 

D. Biohit and authorized distributor(s) will inform authorized laboratories and relevant public health authorities of this EUA, Including the terms and conditions herein, and any updates made to Biohit product and authorized labeling.

 

 

E. Through a process of inventory control, Biohit and authorized distributor(s) will maintain records of the authorized laboratories to which they distribute the test and number of tests they distribute.

 

 

/s/ XX

 

 

 

 

 

F. Biohit and authorized distributor(s) will collect information on the performance of Biohit product. Biohit will report to FDA any suspected occurrence of false positive and false negative results and significant deviations from the established performance characteristics of the product of which Biohit become aware.

 

 

G. Biohit and authorized distributor(s) are authorized to make available additional Information relating to the emergency use of Biohit product that is consistent with, and does not exceed, the terms of this letter of authorization.

 

 

H. Biohlt and authorized distributor(s) will make available the internal control material or other authorized control materials at the same time as Biohit's product.

 

 

I. Biohit and authorized distributor(s) will make available the SARS-CoV-2 lgM and IgG Positive Control(s) and Negative Control by July 3, 2020 (refer to condition Y).

 

 

/s/ XX

 

- - - - - - - - - - - - -

 

 

 

Terms:

 

1. ThermoGenesis should provide the necessary documents and materials required by FDA to finish the authorization.

 

2. ThermoGenesis agrees to purchase at $ [**] USD per test before [**] purchase quantity, after the [**] quantity is finished, BIOHIT agrees to sell at $ [**] USD per test to ThermoGenesis.

 

3. For further cooperation and purchase, ThermoGenesis and BIOHIT should sign the purchase agreement to discuss more specific details.

 

 

 

 

 

BIOHIT HealthCare Co., ltd.

 

Sign:     /s/ Liu Feng

 

Date:     August 11, 2020

 

 

 

ThermoGenesis Holdings, Inc.

 

 

Sign: /s/ Chris Xu, Ph.D. / CEO

 

Date: August 11, 2020

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}]]